An Open Label, Randomised, Two-way Crossover Scintigraphic Study to Investigate Lung Deposition of Radiolabelled OligoG Delivered as a Dry Powder and as a Nebulised Solution in Cystic Fibrosis Patients

Trial Profile

An Open Label, Randomised, Two-way Crossover Scintigraphic Study to Investigate Lung Deposition of Radiolabelled OligoG Delivered as a Dry Powder and as a Nebulised Solution in Cystic Fibrosis Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs OligoG (Primary) ; Oligosaccharides
  • Indications Cystic fibrosis
  • Focus Pharmacokinetics
  • Sponsors AlgiPharma
  • Most Recent Events

    • 05 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov .
    • 24 Apr 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2014 to 1 Nov 2014.
    • 24 Apr 2014 According to the ClinicalTrials.gov record, trial status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top